BioSpace News Archive

Well-established medical guidelines recommend biomarker testing for all patients with metastatic colon cancer, but new research shows this may not be consistent with actual patterns of care

Paula Mabee, the Nolop Distinguished Professor in the Department of Biology at the University of South Dakota, has been selected as the Chief Scientist and Observatory Director of the National Ecological Observatory Network (NEON).

Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary transdermal DermaSys® drug delivery technology currently focused on sexual health and pain, today announced top-line results from the European Phase 3 study, “FM57” of its lead product candidate, MED2005, for the treatment of erectile dysfunction (ED).

Kaiser Permanente, Alliance for a Healthier Generation and Discovery Education partner to deliver Resilience in School Environments initiative that addresses the social and emotional health of millions of faculty, staff and students

Cergentis announced the launch of TLA for complete cancer gene sequencing and reported superior data over conventional diagnostic and gene sequencing techniques in FFPE tumour samples.

Nordic Nanovector ASA reports an update on its LYMRIT 37-05 Phase 1 trial of Betalutin® in patients with relapsed/refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, announced today that Elan Ezickson, has joined the Company’s Board of Directors.

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing of its underwritten public offering of 14,516,130 shares of its common stock at the public offering price of $15.50 per share for total gross proceeds to Momenta of approximately $225.0 million.

CStone Pharmaceuticals announced that the Company has recently received the approval from the Human Research Ethics Committee in Australia, and the acknowledgement from Australia’s Therapeutic Goods Administration on the Phase I clinical trial of CS3005.

Novel imaging agent allows detection of lymph node metastases at earlier stage, allowing more effective treatment